The second batch of high-value consumables centralized procurement identified six categories of these companies affected

category:Finance
 The second batch of high-value consumables centralized procurement identified six categories of these companies affected


The first batch of high-value consumables coronary stent procurement in the country has just settled, and the second batch has followed.

According to the notice on rapid data collection and price detection of the second batch of high value medical consumables issued by the medical insurance bureau, the list of the second batch of medical consumables mainly includes six categories: artificial hip joint, artificial knee joint, defibrillator, occluder, orthopedic materials and stapler.

The first batch of high-value consumables only involved one kind of coronary stent, while the second round greatly expanded the number of consumables. The notice involved as many as 10000 pieces of product information, specific to specifications and models about 320000 pieces. At the same time, the notice requires to supplement the first batch of vascular interventional products, non vascular interventional products, pacemakers and ophthalmic products.

The notice also requires all provinces to complete the comparison and correlation between the second list of medical consumables and the provincial platform medical consumables before December 31, 2020 data upload, and complete the supplementary transmission of historical data before February 28, 2021. This means that the second batch of high-value consumables will be purchased around the second quarter of 2021.

The second batch of high-value consumables, mainly involving cardiovascular and orthopedic consumables, are the two largest sales of high-value medical consumables.

Among orthopedic consumables, artificial hip joint and artificial knee joint involve the largest number of domestic listed companies, including Aikang medical (01789. HK), Dabo medical (002901. SZ), Chunli medical (01858. HK), Weigao (01066. HK), minimally invasive medical (00853. HK), etc. At present, the market share in this field is mainly occupied by foreign brands, and the market share of domestic brands will be increased by centralized purchase or by a large margin.

The collection of these varieties has been rehearsed in some provinces and cities. Since 2019, 50% of the provincial-level consumables have been reduced. For example, in the second batch of high-value consumables held by Jiangsu Medical Insurance Bureau in September 2019, the average reduction rate of orthopedic artificial hip joint was 47.20%.

According to the experience of the first batch of national centralized purchase of high-value consumables, due to the larger market involved and the concentrated participation of enterprises, the final bid price drop may be much higher than that of local centralized purchase. In the quotation of national centralized procurement on November 5, the highest reduction rate of coronary stent was 96%, which was far higher than that of local centralized procurement.

As the number of varieties involved in the second batch of high-value consumables is far more than that of the first batch, the market shock may be no less than that of coronary stent centralized procurement. Some of them may be shortlisted in the second batch of centralized purchasing listed companies, and have actually been injured in the first round of centralized purchasing.

For example, the second batch of artificial knee joint will affect Aikang medical, Chunli medical and minimally invasive medical treatment. Among them, four products of minimally invasive medical were shortlisted in the first centralized purchase, and the cumulative intended purchase volume was about 390000, accounting for about 36% of the total, which was one of the most affected enterprises.

Source: interface news Author: Fan Jiazhi, editor in charge: Wang Xiaowu_ NF